ClickSoftware Technologies Slumps On Earnings (CKSW, CEL, TROX, KEQU, PTN)

ClickSoftware Technologies Ltd (NASDAQ:CKSW) declined 9.22% to $7.58 after the Company provided an update on the second quarter results. The Company expects revenues for the second quarter to be about $22.5 million, representing around 9% year-over-year growth. The Company estimates net income to be about breakeven. Non-GAAP net income is expected to be about $1 million or $0.03 per share. The Company estimates cash, cash-equivalents, short and long-term investments were approximately $50 million as of June 30, 2012.

Cellcom Israel Ltd (NYSE:CEL) decreased 8.21% to $6.37. Cellcom Israel denied rumors that controlling shareholder Nochi Danker held preliminary with David Azrieli about a sale of the mobile carrier. David Azrieli's Azrieli Group Ltd also denied the rumors.

Tronox Limited  (NYSE:TROX) plunged 11.62% to $113.0 on a traded volume of 140k shares. The stock opened at $124.50. The 52-week range of the stock $74.75 and $190.0.The Company has Price/Sales ratio of 1.13 and Price/Book ratio of 2.28. The 50-Day Moving Average and 200-Day Moving Average prices is $139.64 and $139.64 respectively.

Kewaunee Scientific Corporation (NASDAQ:KEQU) soared 2.66% to $12.38. Recently, the Board of Directors adopted the Kewaunee Scientific Corporation Fiscal Year 2013 Incentive Bonus Plan for Chief Executive Officer, President and Chief Operating Officer and certain managers. The Plan provides for a bonus pool and bonus payouts to eligible participants.

Palatin Technologies Inc (NYSEAMEX: PTN) jumped up 18.77% to $0.760. The Company has entered into a definitive securities agreement and priced a private placement of 3,873,000 shares of its common stock. Series A warrants to purchase 31,988,151 shares of its common stock and Series B warrants to purchase 35,488,380 shares of its common stock. The private placement is expected to close around   July 5, 2012The Company intends to use the proceeds from this offering for general corporate purposes and working capital. This also includes clinical trial program with bremelanotide for female sexual dysfunction, preclinical and clinical development of its melanocortin receptor-1 peptide program.